MOSCOW & SAINT-LAURENT-DU-VAR, France--(BUSINESS WIRE)--NovaMedica LLC, a Russian pharmaceutical company, and Horus Pharma SL, a French company dedicated to the development of innovative products treating ophthalmic diseases, have signed a partnership agreement that grants NovaMedica exclusive rights to commercialize a portfolio of products in Russia and the Commonwealth of Independent States (CIS).
Products include: hylaluronic acid containing ILast to assist healing of the eyelids following surgery; easy to swallow Macula-Z-Oro combining essential vitamins for eye health Antiseptic; and single dose and preservative-free Vitamine B12 eye drops to promote healing.
The first sales from this portfolio of products are expected in 2015, and NovaMedica will have the option to commercialize future Horus Pharma products currently under development with special focus on Glaucoma treatment.
“With a sizeable and continually expanding commercial portfolio from Clearside Biomedical, ReVision Optics, SiFi, and now Horus Pharma, NovaMedica will deliver a unique and innovative combination of products and technologies to the Russian ophthalmic market,” said Fabrice Egros, Chief Operating Officer of NovaMedica. “This will enable Russian eye care doctors to address a wide variety of ophthalmic problems and bring substantial benefits to Russian patients.”
Horus Pharma CEO Claude Claret also welcomes this new international partnership which opens up new pharmaceutical perspectives in Russia.
“NovaMedica is a team of professionals with deep and thorough expertise of the Russian biotech market — an ideal partner capable of registering and effectively marketing our products. We are delighted to be able to tap demand from the rapidly growing ophthalmology market in Russia and other CIS countries,” said Claude Claret. “This agreement also offers an opportunity for further business activities and, undoubtedly, it will contribute to a broader availability of advanced therapies to Russian patients.”
NovaMedica is a Russian pharmaceutical company established in 2012 by DRI Holdings Limited, a portfolio company of Domain Associates LLC, and Russian investment corporation RUSNANO, which implements government policy of fostering the development of hi-tech industries. The company’s strategy is aimed at localizing production of a wide range of new medicines and technologies in the Russian market, including screening and registration of new pharmaceuticals, and the creation of innovative GMP-standard manufacturing facilities. www.novamedica.com
Horus Pharma is a French pharmaceutical company specialized in ophthalmology and dermatology. Created in 2003 by Martine and Claude Claret in Saint-Laurent-du-Var near Nice, Horus Pharma is an independent and innovative laboratory that markets over 30 specialized treatments dedicated to the eye health and comfort. More information available at www.horus-pharma.fr